Found: 179
Select item for more details and to access through your institution.
Human prolyl hydroxylase domain 2 reacts with O<sub>2</sub> and 2-oxoglutarate to enable formation of inactive Fe(III).2OG.hypoxia-inducible-factor α complexes.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-75761-y
- By:
- Publication type:
- Article
Sifting Through the Multitude of Novel Therapies for Prostate Cancer.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 14, p. 1792
- By:
- Publication type:
- Article
The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells.
- Published in:
- Prostate, 1996, v. 29, n. 3, p. 177, doi. 10.1002/(SICI)1097-0045(199609)29:3<177::AID-PROS3>3.0.CO;2-B
- By:
- Publication type:
- Article
Subcutaneous Atezolizumab: A Jab Without a Benefit.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 1, p. 134, doi. 10.1002/cpdd.1061
- By:
- Publication type:
- Article
More than an accessory: implications of type III transforming growth factor-β receptor loss in prostate cancer.
- Published in:
- BJU International, 2010, v. 105, n. 7, p. 913, doi. 10.1111/j.1464-410X.2009.08999.x
- By:
- Publication type:
- Article
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2009, v. 103, n. 12, p. 1636, doi. 10.1111/j.1464-410X.2008.08327.x
- By:
- Publication type:
- Article
Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
- Published in:
- BJU International, 2008, v. 102, n. 11, p. 1694, doi. 10.1111/j.1464-410X.2008.07913.x
- By:
- Publication type:
- Article
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
- Published in:
- BJU International, 2008, v. 102, n. 5, p. 617, doi. 10.1111/j.1464-410X.2008.07629.x
- By:
- Publication type:
- Article
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
- Published in:
- BJU International, 2008, v. 101, n. 7, p. 884, doi. 10.1111/j.1464-410X.2007.07342.x
- By:
- Publication type:
- Article
Secondary hormonal therapy for prostate cancer: what lies on the horizon?
- Published in:
- BJU International, 2008, v. 101, n. 3, p. 271, doi. 10.1111/j.1464-410X.2007.07236.x
- By:
- Publication type:
- Article
Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
- Published in:
- BJU International, 2007, v. 100, n. 6, p. 1245, doi. 10.1111/j.1464-410X.2007.07173.x
- By:
- Publication type:
- Article
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
- Published in:
- BJU International, 2007, v. 99, n. 5, p. 1047, doi. 10.1111/j.1464-410X.2007.06763.x
- By:
- Publication type:
- Article
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
- Published in:
- BJU International, 2007, v. 99, n. 3, p. 525, doi. 10.1111/j.1464-410X.2006.06654.x
- By:
- Publication type:
- Article
A retrospective study of the time to clinical endpoints for advanced prostate cancer.
- Published in:
- BJU International, 2005, v. 96, n. 7, p. 985, doi. 10.1111/j.1464-410X.2005.05798.x
- By:
- Publication type:
- Article
CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00123
- By:
- Publication type:
- Article
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/pharmaceutics14091933
- By:
- Publication type:
- Article
A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 7, p. 997, doi. 10.3390/pharmaceutics13070997
- By:
- Publication type:
- Article
Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide.
- Published in:
- Clinical Genitourinary Cancer, 2009, v. 7, n. 2, p. E37, doi. 10.3816/CGC.2009.n.020
- By:
- Publication type:
- Article
Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 3, p. 896, doi. 10.3390/ijms21030896
- By:
- Publication type:
- Article
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1386190
- By:
- Publication type:
- Article
A Phase I/II Study of High-Dose Tamoxifen in Combination with Vinblastine in Patients with Androgen-Independent Prostate Cancer.
- Published in:
- Acta Oncologica, 2003, v. 42, n. 3, p. 195, doi. 10.1080/02841860310010718
- By:
- Publication type:
- Article
Flutamide Withdrawal and Concomitant Initiation of Aminoglutethimide in Patients with Hormone Refractory Prostate Cancer.
- Published in:
- Acta Oncologica, 1996, v. 35, n. 6, p. 763, doi. 10.3109/02841869609084015
- By:
- Publication type:
- Article
VEGF inhibition and metastasis Possible implications for antiangiogenic therapy.
- Published in:
- Chinese Journal of Lung Cancer, 2009, v. 12, n. 8, p. 915, doi. 10.3779/j.issn.1009-3419.2009.08.17
- By:
- Publication type:
- Article
Clinical protocol: Feasibility of evaluating abemaciclib neuropharmacokinetics of diffuse midline glioma using intratumoral microdialysis.
- Published in:
- PLoS ONE, 2023, v. 18, n. 9, p. 1, doi. 10.1371/journal.pone.0291068
- By:
- Publication type:
- Article
Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat.
- Published in:
- ChemMedChem, 2021, v. 16, n. 13, p. 2082, doi. 10.1002/cmdc.202100133
- By:
- Publication type:
- Article
Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides.
- Published in:
- ChemMedChem, 2018, v. 13, n. 19, p. 2080, doi. 10.1002/cmdc.201800263
- By:
- Publication type:
- Article
The androgen receptor gene and its influence on the development and progression of prostate cancer.
- Published in:
- Journal of Pathology, 2001, v. 195, n. 2, p. 138, doi. 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y
- By:
- Publication type:
- Article
Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 2, p. 261, doi. 10.1111/bjh.18558
- By:
- Publication type:
- Article
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
- Published in:
- Molecular Cancer, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1476-4598-13-91
- By:
- Publication type:
- Article
PHARMACOKINETICS OF ELEMENTAL PLATINUM (ULTRAFILTRATE AND TOTAL) AFTER A THIRTY MINUTE INTRAVENOUS INFUSION OF ORMAPLATIN.
- Published in:
- Biopharmaceutics & Drug Disposition, 1997, v. 18, n. 4, p. 347, doi. 10.1002/(SICI)1099-081X(199705)18:4<347::AID-BDD23>3.0.CO;2-O
- By:
- Publication type:
- Article
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 833, doi. 10.1002/ajh.26527
- By:
- Publication type:
- Article
Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer.
- Published in:
- Journal of Racial & Ethnic Health Disparities, 2024, v. 11, n. 1, p. 492, doi. 10.1007/s40615-023-01534-4
- By:
- Publication type:
- Article
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.
- Published in:
- Scientific Reports, 2016, p. 30038, doi. 10.1038/srep30038
- By:
- Publication type:
- Article
Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0126672
- By:
- Publication type:
- Article
Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance.
- Published in:
- PLoS ONE, 2014, v. 9, n. 5, p. 1, doi. 10.1371/journal.pone.0095532
- By:
- Publication type:
- Article
Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression.
- Published in:
- PLoS ONE, 2011, v. 6, n. 5, p. 1, doi. 10.1371/journal.pone.0020372
- By:
- Publication type:
- Article
Safety and Feasibility of Long-term Intravenous Sodium Nitrite Infusion in Healthy Volunteers.
- Published in:
- PLoS ONE, 2011, v. 6, n. 1, p. 1, doi. 10.1371/journal.pone.0014504
- By:
- Publication type:
- Article
Local and Systemic Antitumor Effects of Photo‐activatable Paclitaxel Prodrug on Rat Breast Tumor Models.
- Published in:
- Photochemistry & Photobiology, 2020, v. 96, n. 3, p. 668, doi. 10.1111/php.13202
- By:
- Publication type:
- Article
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2006, v. 80, n. 2, p. 192, doi. 10.1016/j.clpt.2006.05.003
- By:
- Publication type:
- Article
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2006, v. 79, n. 1, p. 1, doi. 10.1016/j.clpt.2005.09.006
- By:
- Publication type:
- Article
Relationship of systemic exposure to unbound docetaxel and neutropenia.
- Published in:
- Clinical Pharmacology & Therapeutics, 2005, v. 77, n. 1, p. 43, doi. 10.1016/j.clpt.2004.09.005
- By:
- Publication type:
- Article
Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches.
- Published in:
- Clinical Pharmacology & Therapeutics, 2003, v. 74, n. 5, p. 509, doi. 10.1016/j.clpt.2003.08.004
- By:
- Publication type:
- Article
Preliminary Pharmacokinetics (PK) of COL-3, A Matrix Metalloproteinase (MMP) Inhibitor.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 65, n. 2, p. 195, doi. 10.1016/S0009-9236(99)80308-7
- By:
- Publication type:
- Article
Polypharmacy in View of Advances in Cancer Treatment.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 9, p. 1055
- By:
- Publication type:
- Article
Pharmacy Education: Back to the Basics?
- Published in:
- 2003
- By:
- Publication type:
- Editorial
Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen-Independent Prostate Cancer.
- Published in:
- Pharmacotherapy, 2003, v. 23, n. 3, p. 315
- By:
- Publication type:
- Article
2-Methoxyestradiol, a Promising Anticancer Agent.
- Published in:
- Pharmacotherapy, 2003, v. 23, n. 2, p. 165, doi. 10.1592/phco.23.2.165.32088
- By:
- Publication type:
- Article
Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
- Published in:
- World Journal of Urology, 2004, v. 22, n. 6, p. 425, doi. 10.1007/s00345-004-0443-7
- By:
- Publication type:
- Article